Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice : Clinical outcomes in a single centre cohort after long-term follow-up
Corrochano, Mariana (Institut d'Investigació Biomèdica Sant Pau)
Jiménez, Beatriz (Institut d'Investigació Biomèdica Sant Pau)
Millón Caño, Juan Antonio (Institut d'Investigació Biomèdica Sant Pau)
Gich, Ignasi (Institut d'Investigació Biomèdica Sant Pau)
Rambla, M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Gil, Eva (Institut d'Investigació Biomèdica Sant Pau)
Caparrós, P. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Macho, Raquel (Institut d'Investigació Biomèdica Sant Pau)
Souto, Juan Carlos (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very promising model of care for oral anticoagulation in terms of efficacy and safety. In comparison with other management models of VKA therapy, the number of scientific publications supporting the advantages of PSM is more limited. Currently, most of the scarce information comes from randomized clinical trials. Moreover, a small number of studies have assessed PSM of VKA therapy in real life conditions. We analyzed clinical outcomes of 927 patients in a single center (6018. 6 patient-years of follow-up). Recruitment took place between 2002 and 2017. All patients followed a structured training program, conducted by specialized nurses. Fifty percent of individuals had a mechanical heart valve (MHV), 23% suffered from recurrent venous thromboembolism (VTE) or high-risk thrombophilia, and 13% received VKA therapy because of atrial fibrillation (AF). Median follow-up was 6. 5 years (range 0. 1-15. 97 years), median age was 58. 1 years (IQR 48-65. 9) and 46. 5% were women. The incidence of major complications (either hemorrhagic or thromboembolic) was 1. 87% patient-years (pt-ys) with a 95% CI of 1. 54-2. 27. The incidence of major thromboembolic events was 0. 86% pt-ys (95% CI 0. 64-1. 13) and that of major hemorrhagic events was 1. 01% pt-ys (95% CI 0. 77-1. 31). The incidence of intracranial bleeding was 0. 22% pt-ys (95% CI 0. 12-0. 38). In terms of clinical indication for VKA therapy, the incidence of total major complications was 2. 4% pt-ys, 2. 0% pt-ys, 0. 9% pt-ys and 1. 34% pt-ys for MHV, AF, VTE and other (including valvulopathies and myocardiopathies), respectively. Clinical outcomes were worse in patients with multiple comorbidities, previous major complications during conventional VKA therapy, and in older individuals. The percentage of time in therapeutic range (TTR) was available in 861 (93%) patients. Overall, the mean (SD) of TTR was 63. 6 ± 13. 4%, being higher in men (66. 2 ± 13. 1%) than women (60. 6 ± 13. 2%), p < 0. 05. In terms of clinically relevant outcomes (incidence of major complications and mortality), PSM in real life setting seems to be a very good alternative in properly trained patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Anticoagulation ; Clinical practice ; Complications ; Management ; Vitamin K antagonists
Publicat a:	BMC Cardiovascular disorders, Vol. 20 Núm. 1 (october 2020) , p. 166, ISSN 1471-2261

DOI: 10.1186/s12872-020-01448-7
PMID: 32276619

13 p, 462.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats